Mortality: The challenges of estimating biological age

A comparison of nine different approaches over a period of 20 years reveals the most promising indicators for biological age.
  1. Alexey Moskalev  Is a corresponding author
  1. Ural Branch of Russian Academy of Sciences, Russian Federation
  2. Syktyvkar State University, Russian Federation
  3. Russian Academy of Sciences, Russian Federation

To see if treatments to ward off aging work, first we need a way to measure biological age reliably (Moskalev, 2019). Biological age is a complex parameter involving the calendar age of a person, their health as relating to their age, and medical signs of when they might die of old age. Historically, the first estimates of biological age were based on markers that could be measured in the clinic (such as inflammation, glucose resistance, and endocrine markers) and on functional tests (such as cognitive function and cardiorespiratory fitness; reviewed in Jia et al., 2017). Such markers have a direct clinical interpretation, but even if they predict mortality better than passport age, it is unclear to what extent they measure biological aging itself, rather than health deterioration for other reasons. Additionally, these markers often only work well as averaged indicators in very large samples, and vary a lot between individuals. However, it may be possible to overcome these limitations by using artificial intelligence to generate models using several aging biomarkers (Zhavoronkov et al., 2019).

Other approaches, based on a deeper understanding of the molecular and cellular causes of aging, include measuring the levels of p16 (a marker for cellular senescence or when a cell stops dividing) and measuring the telomere length in leukocytes (biological age increases as telomere length decreases; Waaijer et al., 2012; Epel et al., 2009). Theoretically, these markers should be more sensitive to early signs of aging (as opposed to mortality and frailty) but, similar to clinical markers for individual patients, they lack robustness and reproducibility. This is because aging is a multi-level process, so markers of individual mechanisms cannot cover all its aspects.

A third approach is to use ‘omics’ (that is, to analyze the transcriptome, methylome, proteome and metabolome). Changes in the ‘omes’ are the result of changes in the organism at different levels, making them a useful way to approach the complexity of the aging process. Using this approach, there is no single biological age, but rather a metabolic, proteomic or methylome age. Multi-omics approaches have also been used to assess the rate of aging (Solovev et al., 2020).

Within omics, analyses of DNA methylation or epigenetic clocks are the most robust indicator of age-related changes and have become a booming area of research (Bell et al., 2019). But questions still remain. To what extent are epigenetic clocks a function of age, and to what extent part of biological aging? How does the epigenome change with age? How closely are epigenetic clocks associated with mortality? Is it possible to reverse the epigenetic age, for example through lifestyle changes or interventions? Diet, exercise, education and lifestyle factors seem to be able to influence the rate of aging according to the epigenetic clock (Quach et al., 2017; Gensous et al., 2019; Sae-Lee et al., 2018). Certain drugs can slow down the epigenetic clock in cells cultured in the lab (Horvath et al., 2019) and certain treatments have also proved to be effective in vivo (Chen et al., 2019; Fahy et al., 2019).

Now, in eLife, Sara Hägg from the Karolinska Institute and colleagues from the University of California Riverside, Indiana University Southeast and Jönköping University – with Xia Li as first author – study how nine different methods to estimate biological age change over time in a cohort of 845 middle-aged and older individuals from Sweden who were studied over a period of 20 years (Li et al., 2020). Three of the biological ages measured were functional (cognitive function, functional aging index, and frailty index) and four were based on the levels of DNA methylation (called Horvath, Hannum, PhenoAge and GrimAge). The other two were telomere length (measured by qPCR) and physiological age (calculated as a composite score of clinical measurements such as body-mass index or waist circumference, and blood biomarkers such as hemoglobin or cholesterol).

This study is unique because it compares several approaches at once and evaluates how the measurements change over time: functional data and biological samples were collected nine times between 1986 and 2014. The profiles for the three functional measurements indicated that accelerated aging started around the age of 70, whereas the other biological ages showed linear growth with time.

The authors found sex differences in the mean levels of the different biological ages. Women exhibited longer telomere length and lower DNA methylation age compared to men, but also averaged higher in two of the three functional estimates. Telomere length showed the weakest correlations with both chronological age and with the other measurements. The highest correlations were between two of the DNA methylation ages (Horvath and Hannum), and between the functional aging index and the other two functional biological ages. Regarding the ability of biological ages to predict age-related mortality, one of the functional estimates (frailty index) and one of the methylation clocks (GrimAge) were the best predictors, while telomere length was the worst.

These results indicate that methylation age and frailty index are the most promising approaches to estimating biological age, and underline the value of assessing these estimates overtime in the same population.

References

  1. Book
    1. Moskalev A
    (2019) Introduction
    In: Moskalev A, editors. Biomarkers of Human Aging. Cham: Springer International Publishing. pp. 1–4.
    https://doi.org/10.1007/978-3-030-24970-0_1

Article and author information

Author details

  1. Alexey Moskalev

    Alexey Moskalev is in the Institute of Biology, Komi Science Center, Ural Branch of the Russian Academy of Sciences, and Syktyvkar State University, both in Syktyvkar, Russia, and the Engelhard Institute for Molecular Biology, Russian Academy of Sciences, Moscow, Russia

    For correspondence
    amoskalev@list.ru
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3248-1633

Publication history

  1. Version of Record published: February 11, 2020 (version 1)

Copyright

© 2020, Moskalev

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,007
    Page views
  • 342
    Downloads
  • 16
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexey Moskalev
(2020)
Mortality: The challenges of estimating biological age
eLife 9:e54969.
https://doi.org/10.7554/eLife.54969

Further reading

    1. Epidemiology and Global Health
    David Robert Grimes
    Research Advance Updated

    In biomedical science, it is a reality that many published results do not withstand deeper investigation, and there is growing concern over a replicability crisis in science. Recently, Ellipse of Insignificance (EOI) analysis was introduced as a tool to allow researchers to gauge the robustness of reported results in dichotomous outcome design trials, giving precise deterministic values for the degree of miscoding between events and non-events tolerable simultaneously in both control and experimental arms (Grimes, 2022). While this is useful for situations where potential miscoding might transpire, it does not account for situations where apparently significant findings might result from accidental or deliberate data redaction in either the control or experimental arms of an experiment, or from missing data or systematic redaction. To address these scenarios, we introduce Region of Attainable Redaction (ROAR), a tool that extends EOI analysis to account for situations of potential data redaction. This produces a bounded cubic curve rather than an ellipse, and we outline how this can be used to identify potential redaction through an approach analogous to EOI. Applications are illustrated, and source code, including a web-based implementation that performs EOI and ROAR analysis in tandem for dichotomous outcome trials is provided.

    1. Epidemiology and Global Health
    Qixin He, John K Chaillet, Frédéric Labbé
    Research Article

    The establishment and spread of antimalarial drug resistance vary drastically across different biogeographic regions. Though most infections occur in sub-Saharan Africa, resistant strains often emerge in low-transmission regions. Existing models on resistance evolution lack consensus on the relationship between transmission intensity and drug resistance, possibly due to overlooking the feedback between antigenic diversity, host immunity, and selection for resistance. To address this, we developed a novel compartmental model that tracks sensitive and resistant parasite strains, as well as the host dynamics of generalized and antigen-specific immunity. Our results show a negative correlation between parasite prevalence and resistance frequency, regardless of resistance cost or efficacy. Validation using chloroquine-resistant marker data supports this trend. Post discontinuation of drugs, resistance remains high in low-diversity, low-transmission regions, while it steadily decreases in high-diversity, high-transmission regions. Our study underscores the critical role of malaria strain diversity in the biogeographic patterns of resistance evolution.